Applied Clinical Trials-04-01-2023

Through grassroots patient education, local pharmacies serve as a pivotal doorway to improving access to trials.

Determining if an EAC is at risk and key actions to mitigate trial impact.

Strategies for intervention—or, ideally, averting potential pitfalls from the onset.

Statistical methods used via this technique in centralized monitoring.

CDISC standards applicable to ePRO and other types of eCOA are still behind in the current regulatory landscape.

PV is on the road to becoming a leader, not a follower, in leveraging drug lifecycle information for clinical trials and to inform clinical care.

Identifying key differences between PV and drug safety.

The hopes for increased transparency in clinical research beginning to take shape as sponsors get up to speed with new reporting obligations.

The key issues for industry and FDA as the Orphan Drug Act hits its 40th anniversary.